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A B S T R A C T
Aims: Emerging evidence show that patients with chronic pancreatitis (CP) and abdominal pain have structural
and functional alterations in the central nervous system. The aim was to investigate cerebral metabolic sig-
natures in CP and the associations to various risk factors/clinical characteristics and patient outcomes.
Methods: Magnetic resonance spectroscopy was used to measure brain metabolites in the anterior cingulate
cortex (ACC), insula, prefrontal cortex and the parietal region in patients with CP and healthy controls. Subgroup
analyses based on disease characteristics (alcoholic etiology of CP, diabetes and opioid treatment) were per-
formed. Finally, relations to abdominal pain symptoms and quality of life scores were explored.
Results: Thirty-one patients with CP (mean age 58.5 ± 9.2 years) and 23 healthy controls (54.6 ± 7.8 years)
were included. Compared to healthy controls, patients had increased glutamate/creatine (glu/cre) levels in the
ACC (1.24 ± 0.17 vs. 1.13 ± 0.21, p= .045) and reduced parietal N-acetylaspartate/creatine (NAA/cre) levels
(1.44 ± 0.18 vs. 1.54 ± 0.12, p= .027). Patients with alcoholic etiology of CP had significant lower levels of
parietal NAA/cre as compared to patients without alcoholic etiology and healthy controls (p < .006). Patients
with a high level of ACC glu/cre reported more severe abdominal pain than their counterparts with a low level of
ACC glu/cre (pain score 4.1 ± 2.7 vs.1.9 ± 2.3, p= .039).
Conclusions: Cerebral spectroscopy revealed novel and complementary information on central pain mechanisms and
alcohol mediated toxic effects in patients with CP. Our data suggest that cingulate glutamate levels associate with the
patients clinical pain symptoms, while parietal NAA levels more likely associate with an alcoholic etiology of CP.
1. Introduction
Chronic pancreatitis (CP) is characterized by long-standing inflamma-
tion of the pancreas resulting in morphological and functional alterations.
Chronic abdominal pain is the hallmark symptom of CP and, in addition to
changes in the pancreas and peripheral nerves, the chronic pain syndrome
has been associated with an abnormal central pain processing and structural
brain abnormalities (Olesen et al., 2013; Lelic et al., 2014; Dimcevski et al.,
2007; Frøkjær et al., 2012; Frøkjær et al., 2011; Muthulingam et al., 2018).
No published studies have, to the best of our knowledge, investigated
whether cerebral metabolic alterations are present in patients with CP as
compared to healthy subjects.
Magnetic resonance spectroscopy can be used to reveal brain metabo-
lites such as N-acetylaspartate (NAA) recognized as a marker of neuronal
functionality and density, creatine (cre) involved in neuronal energy
metabolism, glutamate (glu) that is a neurotransmitter, myo-inositol (mI)
that is a glial marker, and choline containing compounds associated with
membrane turnover (Marjańska et al., 2017). These metabolites present
potential indicators of neuronal dysfunction/alterations.
Magnetic resonance spectroscopy has previously been used to show that
patients with chronic pain have a different neurometabolic status compared
to healthy controls (Kameda et al., 2018; Ito et al., 2017; Feraco et al., 2011;
Lv et al., 2018). Especially, higher levels of glu/cre and glx/cre (glx: glu-
tamate and glutamine) in the anterior cingulate cortex (ACC) were de-
monstrated in chronic pain patients (Kameda et al., 2018; Ito et al., 2017). A
study with Crohn's disease patients with abdominal pain also revealed
higher levels of ACC glu/cre, than patients without abdominal pain and
healthy controls (Lv et al., 2018). This indicates that magnetic resonance
spectroscopy is a valid method to obtain information of pain related me-
tabolic changes in the brain.
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In this present study, magnetic resonance spectroscopy was used to in-
vestigate brain metabolite levels in patients with CP as compared to healthy
controls. Although previous studies have shown that brain changes may be
associated to chronic abdominal pain (Olesen et al., 2013; Lelic et al., 2014;
Dimcevski et al., 2007; Frøkjær et al., 2012; Frøkjær et al., 2011;
Muthulingam et al., 2018), it is likely that brain alterations could be caused
by other CP related diseases characteristics, i.e. previous use of alcohol,
diabetes, drug consumption, rather than chronic pain itself. Such factors
need to be taken into consideration as alcohol, diabetes and opioids have
previously been shown to be related to brain alterations (Selvarajah et al.,
2011; Younger et al., 2011; Zahr and Pfefferbaum, 2017). We hypothesized
that patient with CP have increased glu/cre in pain related areas and that
this metabolite may be associated to patient outcomes (abdominal pain and
quality of life). As an additional explanatory hypothesis, we explored the
impact of other CP disease characteristics on brain metabolites in pain re-
lated areas and in white matter rich parietal region which might be vul-
nerable to changes due to alcohol exposure and diabetes (Zahr and
Pfefferbaum, 2017; Hansen et al., 2019).
Thus, the aims were 1) to assess brain metabolites in patients with CP as
compared to healthy controls in areas involved in pain processing (ACC,
insula and prefrontal cortex) and in the parietal region, 2) to compare brain
metabolite levels in subgroups with different disease characteristics (alco-
holic etiology, diabetes, opioids treatment), and finally 3) to explore asso-
ciations between altered brain metabolites in pain related areas and patient
outcome (abdominal pain and quality of life).
2. Material and methods
2.1. Study population
hirty-five patients with both painful and non-painful CP and 23 healthy
controls were included in this cross-sectional study. The study was con-
ducted at Centre for Pancreatic Diseases, Department of Gastroenterology
and Hepatology and Department of Radiology, Aalborg University Hospital,
Denmark. All subjects were screened by a medical doctor before enrollment.
Patients were included if they had a CP diagnosis based on the Mayo Clinic
diagnostic criteria (Layer and DiMagno, 1999) and exclusion criteria were:
inability to undergo MRI, major illness such as cancer, pain syndromes other
than CP and present alcohol or drug abuse. Furthermore, none of the pa-
tients had psychiatric illness, or used psychiatric medication. Age and
gender matched healthy controls were included from our database. Healthy
controls were without chronic pain conditions and any gastrointestinal
symptoms. All subjects were informed about the study orally and in writing,
and they provided informed written consent. Protocols were approved by
the Ethics Committee of Northern Jutland (reference number N-20090008,
N-20130040, N-20170023) and the study was conducted in accordance to
the Declaration of Helsinki.
2.2. Disease characteristics
The electronic medical records were reviewed to obtain information
on pharmacological treatment, diabetes status, and demographic
characteristics including gender, age, etiology and duration of CP.
2.3. Magnetic resonance spectroscopy
Magnetic resonance spectroscopy measurements were obtained using a
3 T GE scanner (GE Signa HDxt, General Electric, Milwaukee, WI, USA). A
standard eight-channel head coil was used and the head was fixed using
foam pads. Single voxel PRESS (Point RESolved Spectroscopy) spectroscopy
were acquired (TR/TE = 2000/30 ms) and total number of scans was 128
(5 min in total) in four different voxels of interests (VOIs), see example in
Fig. 1. The VOIs were positioned in: 1) ACC (20 × 20 × 20 mm) on high
resolution sagittal T2-weighted fast spin echo images in the midline of the
pregenual ACC with the inferior border along the anterior-posterior com-
missure line, 2) right insula (15 × 20 × 50 mm) on high resolution axial
T1-weigthed images and 3) the prefrontal cortex (15 × 15 × 20 mm) on the
high resolution sagittal T2-weighted images, and 4) the parietal region
(15 × 15 × 50 mm) contralateral to the side of the dominant hand, on the
high resolution axial T1-weighted images and placed to cover as much
white matter as possible.
A radiologist reviewed all scans for major structural changes within
the VOIs. Potential scanner drift was monitored with a PRESS spec-
troscopy sequence of a phantom on each day.
LCModel (Version 6.3) was utilized for post-processing (Provencher,
1993). Water scaling and eddy-current correction were performed and
metabolites were fitted in the chemical shift range 0.1–4.0 ppm. NAA/
cre, glu/cre, mI/cre and GPC/cre were analyzed. Metabolites with
Cramér-Rao bounds < 30% were included. Quality measurements
(signal-to-noise ratio (SNR) and full width at half maximum (FWHM))
for all spectra were provided from the analyses in LCModel.
2.4. Patient outcome measurements
Patient outcome measurements (abdominal pain and quality of life)
were assessed using Brief Pain Inventory (BPI) short form (Mendoza et al.,
2006) and the European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) (Aaronson
et al., 1993). The BPI questionnaire evaluates pain at its “worst”, “least”,
“average”, and “now”. All four severity items were used to calculate the
mean BPI pain score. Additionally, the BPI questionnaire measured how
much pain has interfered with daily activities. The BPI pain interference is
calculated as the mean of the seven interference items (Fayers et al., 2001a).
EORTC-QLQ-C3O incorporates three main domains: Global health status,
functional (physical, emotional, role, cognitive, social functioning) scales,
and symptom scales (only the pain item was used). All three domains were
Fig. 1. Positions of voxels of interests: Anterior cingulate cortex (20 ×
20 × 20 mm), insula (15 × 20 × 50 mm), prefrontal cortex (15 × 15 ×
20 mm) and the parietal region (15 × 15 × 50 mm).
T.M. Hansen, et al. NeuroImage: Clinical 23 (2019) 101925
2
analyzed according to the reference manual and presented as mean ±
standard deviation. All three domains measure range in score from 0 to
100. A high score of global health status represents a high quality of life, a
high score for a functional scale represents a healthy functioning, and a high
score for a symptom scale represents a high level of symptomatology
(Fayers et al., 2001b).
2.5. Statistical analyses
Differences of clinical characteristics and brain metabolite levels
between patients and healthy controls were assessed using appropriate
independent-sample t-tests or chi-squared tests. Only brain metabolites
that were significant different between patients and healthy controls
were investigated for further analyses regarding disease characteristics
and patient outcomes.
Patient subgroups were stratified based on their 1) etiology of CP
(alcoholic etiology, no/yes), 2) diabetes status (no/yes), and 3) current
opioid treatment (no/yes). One-way ANCOVAs were conducted to
analyze differences between patient subgroups and healthy controls
controlling for age as covariate.
Patient reported outcomes (BPI pain and quality of life scores) were
compared between patients with high and low glu/cre levels (stratified
on the median metabolite level) using Mann-Whitney's U test. This was
only explored in pain related areas that revealed changed metabolites.
Data are presented as mean ± standard deviation unless otherwise
indicated and p < .05 was considered significant. Statistical analyses
were performed in IBM SPSS Statistics (IBM Corp., Released 2017. IBM
SPSS Statistics for Windows, Version 25.0. Armonk, NY, USA: IBM
Corp.).
3. Results
Of the 35 patients considered for analysis, two patients were ex-
cluded due to poor MRI scan quality and two patients were excluded
due to active alcohol abuse (revealed as ethanol peaks identified at
1.2 ppm in the metabolite spectra). Hence, thirty-one patients (mean
age 58.5 ± 9.2 years) and 23 healthy controls (mean age
54.6 ± 7.8 years) were included for the final analysis. Spectroscopy
data in the parietal region were for technical/logistic reasons only ob-
tained from twenty-five patients. Demographics, clinical characteristics
and brain metabolite levels are presented in Table 1. There were no
significant differences in sex, age and body mass index (BMI) between
Table 1
Overview of demographical data, clinical data and metabolite concentrations.
Patients with chronic pancreatitis Healthy controls p-value
n= 31 n= 23
Sex (M/F) 24/7 14/9 0.188
Age (years) 58.5 ± 9.2 54.6 ± 7.8 0.111
BMI (kg/m2) 23.7 ± 3.8 25.1 ± 2.5 0.129
Duration of CP (years) 10.3 ± 7.9
Alcoholic etiology of CP (no/yes) 13/18
Diabetes (no/yes) 18/13
Pain status (no/yes) 9/22
Opioid treatment (no/yes) 20/11
Magnetic resonance spectroscopy ratios (no unit)
ACC
NAA/cre 1.04 ± 0.13 1.07 ± 0.14 0.415
Glu/cre 1.24 ± 0.17 1.13 ± 0.21 (n=22) 0.045*
mI/cre 0.77 ± 0.16 0.83 ± 0.23 0.328
GPC/cre 0.28 ± 0.03 (n= 29) 0.29 ± 0.06 0.332
Insula
NAA/cre 1.27 ± 0.16 1.30 ± 0.15 0.475
Glu/cre 1.17 ± 0.21 1.13 ± 0.20 0.415
mI/cre 0.67 ± 0.14 0.74 ± 0.11 0.056
GPC/cre 0.23 ± 0.07 (n= 30) 0.24 ± 0.06 0.423
Prefrontal
NAA/cre 1.28 ± 0.09 1.29 ± 0.13 0.771
Glu/cre 1.31 ± 0.22 1.27 ± 0.20 0.430
mI/cre 0.67 ± 0.13 0.72 ± 0.09 0.147
GPC/cre 0.25 ± 0.04 (n= 29) 0.24 ± 0.03 (n= 22) 0.180
Parietal
NAA/cre 1.44 ± 0.18 (n= 25) 1.54 ± 0.12 0.027*
Glu/cre 0.91 ± 0.16 (n= 24) 0.87 ± 0.16 (n= 22) 0.414
mI/cre 0.83 ± 0.16 (n= 25) 0.87 ± 0.23 0.444
GPC/cre 0.33 ± 0.05 (n= 24) 0.34 ± 0.08 0.719
Quality measurements, SNR
ACC 13.7 ± 3.9 14.6 ± 4.9 0.455
Insula 29.0 ± 6.1 28.2 ± 8.9 0.698
Prefrontal 13.6 ± 3.3 13.9 ± 2.5 0.716
Parietal 23.0 ± 4.2 (n= 25) 21.0 ± 6.5 0.191
Quality measurements, FWHM
ACC 0.056 ± 0.016 0.052 ± 0.015 0.360
Insula 0.061 ± 0.010 0.058 ± 0.013 0.305
Prefrontal 0.040 ± 0.009 0.041 ± 0.013 0.807
Parietal 0.044 ± 0.012 (n= 25) 0.045 ± 0.009 0.768
Notes: Data are expressed as mean ± standard deviations unless otherwise stated. * indicates significant findings, p< .05. The number (n) of complete data are
thirty-one and twenty-three for patients and healthy controls, respectively, unless otherwise stated in brackets.
Abbreviations: CP: chronic pancreatitis; M: males; F: females; BMI: body mass index; ACC: anterior cingulate cortex; NAA: N-acetylaspartate; cre: creatine; glu:
glutamate; mI: myo-inositol; GPC: glycerophosphocholine; SNR: signal-to-noise ratio; FWHM = full width at half maximum (ppm).
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patients and controls (all p≥ .11). No significant differences in SNR or
FWHM were found between spectra from the two groups in any of the
four VOIs (all p > .19).
3.1. Brain metabolites in patients with CP and healthy controls
Metabolite levels in the four regions of interest are presented in
Table 1. Patients with CP had increased glu/cre levels in the ACC
(p= .045) and reduced NAA/cre levels in the parietal region (p= .027)
compared to healthy controls. Thus, subsequent subgroup analyses
(section 3.2) were only done in these two areas and associations to
patient outcomes were only explored for ACC glu/cre (section 3.3).
3.2. Brain metabolites in subgroups
Focusing on ACC glu/cre and parietal NAA/cre levels, a significant
association between alcoholic etiology and NAA/cre levels in the par-
ietal region (F = 5.78, p= .006) was found. As seen in Fig. 2, NAA/cre
was lower in patients with alcoholic etiology of CP (n= 14) compared
to patients with non-alcoholic etiology (n= 11) (p= .006) and healthy
controls (n= 23) (p= .005). No differences were seen between pa-
tients without alcoholic etiology and healthy controls (p= .63). Fur-
thermore, no differences were demonstrated in the subgroup analyses
of parietal NAA/cre of diabetes (F = 2.39, p= .10) and opioid treat-
ment (F = 1.95, p= .15). Finally, increased ACC glu/cre levels for
patients were not associated with presence of alcoholic etiology of CP,
diabetes or opioid treatment (all p > .10).
3.3. Brain metabolites in ACC and associations to patient reported outcomes
Patient reported BPI pain and quality of life scores for high and low
metabolites levels of ACC glu/cre are presented in Table 2. Patients
with highest glu/cre levels reported increased average pain scores
(within the last 24 h) compared to their counterparts with lowest levels
of glu/cre (p= .039) and felt worse pain (within the last 24 h) as
compared to patients with lowest glu/cre (p= .046). Patients with high
glu/cre had a trend towards decreased quality of life within the emo-
tional functioning domain (p= .076). No significant differences were
seen for other pain scores or quality of life domains (all p > .8).
4. Discussion
In this study, magnetic resonance spectroscopy measurements were
obtained from four brain areas in patients with chronic pancreatitis and
healthy controls. Patients had increased levels of the excitatory neu-
rotransmitter glutamate in the anterior cingulate cortex, which was
associated with the clinical pain symptoms. Furthermore, as a marker of
neuronal functionality patients had decreased white matter parietal N-
acetylaspartate, which associated with an alcoholic etiology of CP.
4.1. Glutamate and associations to clinical outcomes
Increased glutamate levels in the ACC in patients with CP is a very
relevant finding, since glutamate is an excitatory neurotransmitter
Fig. 2. One-way ANCOVAs were conducted to analyze differences in ACC glu/
cre (anterior cingulate cortex glutamate/creatine) and parietal NAA/cre (N-
acetylaspartate/creatine) levels between patient subgroups and healthy con-
trols. Patient subgroups were stratified based on their 1) etiology of CP (alco-
holic etiology, no/yes), 2) diabetes status (no/yes), and 3) current opioid
treatment (no/yes). * indicates significant findings.
Table 2
Patient reported outcome scores and high/low ACC glu/cre levels. The patient
group were divided in high and low ACC glu/cre levels stratified on median
level.
ACC Glu/cre p-value
High Low
Pain scores (visual analogue scale 0–10) (n= 14) (n= 14)
BPI pain 3.8 ± 2.7 1.9 ± 2.1 0.088
Pain right now 3.3 ± 3.0 1.9 ± 2.2 0.214
BPI interference 2.8 ± 2.0 1.8 ± 2.0 0.165
Pain worst 24 h 4.9 ± 2.9 2.6 ± 3.0 0.046*
Pain least 24 h 2.7 ± 2.8 1.1 ± 1.4 0.083
Pain average 4.1 ± 2.7 1.9 ± 2.3 0.039*
Quality of life (0−100) (n= 13) (n= 14)
Global health 50.6 ± 24.6 63.7 ± 26.9 0.303
Physical functioning 69.2 ± 21.9 81.4 ± 21.3 0.160
Role functioning 64.1 ± 30.3 73.8 ± 31.8 0.327
Emotional functioning 58.3 ± 31.2 76.8 ± 32.9 0.076
Cognitive functioning 64.1 ± 33.2 75.0 ± 31.2 0.376
Social functioning 61.5 ± 35.6 81.0 ± 27.6 0.112
Pain 76.9 ± 54.4 48.2 ± 53.2 0.184
Notes: Data are expressed as mean ± standard deviations. * indicates sig-
nificant findings, p < .05. BPI (Brief Pain Inventory) and quality of life ques-
tionnaires were missing due to non-compliance for three and four patients,
respectively.
Abbreviations: ACC glu/cre; anterior cingulate cortex glutamate/creatine; n:
number of patients included in the analysis, h: hours.
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which has previously been shown to be elevated in the ACC of patients
with chronic pain (Ito et al., 2017). A previous study in patients with
Crohn's disease revealed higher levels of ACC glu/cre in patients with
abdominal pain that correlated with clinical pain scores (Lv et al.,
2018). Along these lines, we demonstrated that CP patients with high
ACC glutamate levels had increased pain symptoms and a trend towards
decreased quality of life for especially the emotional functioning do-
main of the quality of life questionnaire. High ACC glutamate levels
might indicate neuronal hyperexcitability, which is considered to be
important in chronification of neuropathic pain (Boadas-Vaello et al.,
2017). A previous pilot study showed that in CP patients responding to
treatment with transcranial magnetic stimulation, the decrease in pain
was correlated to changes in glutamate and NAA levels in the brain
(Fregni et al., 2011). We found a higher glutamate level in patients with
high pain as compared with those having low pain intensity, whereas
such a correlation was not seen in the study by Fregni et al. (2011).
Several methodological differences between the studies can, however,
explain these differences, as brain metabolites were measured in SII and
the transcranial magnetic stimulation induced increase in glutamate
and NAA may be due to homeostatic mechanisms (Fregni et al., 2011).
One-third of the patients in our study were using opioids, which
potentially could influence the measured metabolite levels. Especially,
decreased levels of ACC glu/cre have been shown during acute mor-
phine and oxycodone treatment (Hansen et al., 2016; Hansen et al.,
2014). Thus, the glutamate level could potentially be underestimated
for patients treated with opioids.
Previous electroencephalography studies suggested that patients
with CP and abdominal pain symptoms have abnormal cerebral pain
processing (Olesen et al., 2011) including functional reorganization in
the cingulate and operculo-insular network (Lelic et al., 2014) and
abnormal central excitability (Olesen et al., 2013). This present study
demonstrates that also metabolic brain alterations in the ACC, poten-
tially reflecting the functional changes due to long-lasting neuropathic-
like pain mechanisms, may be associated to pain symptoms in patients
with CP.
4.2. NAA and associations to alcoholic etiology of chronic pancreatitis
Previous studies in acute pain models and in chronic pain patients
have revealed decreased NAA/cre levels in the ACC (Kameda et al.,
2018; Hansen et al., 2014). In our study, NAA/cre levels were not al-
tered in pain related areas (ACC, insula, prefrontal), but NAA/cre was
decreased in the parietal region. This decrease in parietal NAA was
associated to alcoholic etiology of CP. Since patients with alcoholic
etiology had decreased NAA/cre as compared to patients without al-
coholic etiology and healthy controls (and no difference was present
between patients without alcoholic etiology and healthy controls) this
could indicate that previously excessive consumption of alcohol might
be a significant contributing factor for the decreased parietal NAA le-
vels. NAA is known as a marker of neuronal functionality and density
(Duarte et al., 2012) and magnetic resonance spectroscopy studies have
shown lower levels of NAA in recently sober alcoholics relative to
healthy controls in several brain regions (Zahr and Pfefferbaum, 2017).
Regional cerebral alterations have mainly been reported in the frontal,
temporal and parietal lobes in excessive alcohol consumers (Silveri
et al., 2016). Magnetic resonance imaging studies have shown a specific
vulnerability of white matter to chronic alcohol exposure (Zahr and
Pfefferbaum, 2017), which imply the white matter rich parietal region
to be more sensitive to alcohol related metabolic changes than gray
matter rich brain areas. Alcohol-related CNS pathologies have shown
white matter dysmyelination, demyelination and degeneration (de la
Monte and Kril, 2014). Thus, the level of NAA in white matter may be
related to the general condition of the myelinated axons.
Our data could support a theory that general structural brain
changes and decrease of NAA could be more related to alcohol exposure
(and other related co-factors), while functional brain alternations and
regional glutamate changes are more related to pain mechanisms and
the patients' clinical functioning.
4.3. Methodological considerations
Magnetic resonance spectroscopy measurements were obtained
from predefined VOIs based on the literature, but other areas might also
be relevant to investigate. As this was an explorative study, the sig-
nificance level was not corrected for the number of VOIs or metabolites
tested. Due to the relatively small number of subjects in the subgroup
analyses, caution must be applied when interpreting the subgroup
comparisons. Future studies should include more subjects or a study
design to investigate specific subgroups including a more advanced
multivariate statistical analysis. Finally, in this study, a few patients
had incomplete data sets due to different reasons (non-compliance, data
quality, etc.), and as several of the associations between the glutamate
level and patient outcome pointed in a meaningful direction without
being significant, it may indicate that more subjects will be needed in
future studies to provide enough statistical power.
5. Conclusions
Brain metabolites were altered in patients with chronic pancreatitis.
High level of glutamate in the anterior cingulate cortex was linked to
increased perceived pain, which may indicate a hyperexcitatbility state
of the anterior cingulate cortex in painful chronic pancreatitis. On the
other hand, decreased levels of parietal NAA are likely more related to
the general impact of alcohol on the brain and not chronic pancreatitis
per se. A combination of structural, functional and metabolic brain
assessments should be considered to further explore the multi-faceted
role of the brain in patients with painful chronic pancreatitis.
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